Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intermittent Selumetinib in Advanced Uveal Melanoma
NCT02768766Phase 1Completed
- Start
- Feb 2017
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of selumetinib in Uveal melanoma (UM) (6 arms). Primary endpoint: Maximum Tolerated Dose at 8 weeks. Started Feb 2017; status: completed.
02
Drugs
selumetinib
03
Conditions
Uveal melanoma (UM)
Beyond the preview
Go deeper on NCT02768766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02768766.